300
Participants
Start Date
April 1, 2025
Primary Completion Date
October 3, 2029
Study Completion Date
October 3, 2029
Riliprubart Prefilled Pen (PFP)
Pharmaceutical form: Solution Route of administration: Subcutaneous injection
RECRUITING
Investigational Site Number : 2080002, Aarhus N
RECRUITING
Investigational Site Number : 6880001, Belgrade
RECRUITING
Investigational Site Number : 2500002, Marseille
RECRUITING
Investigational Site Number : 3800003, Genova
RECRUITING
Investigational Site Number : 3800004, Rozzano (MI)
RECRUITING
Investigational Site Number : 3800001, Milan
RECRUITING
Investigational Site Number : 7240004, Majadahonda
RECRUITING
Investigational Site Number : 2500007, Bordeaux
RECRUITING
Alabama Neurology Associates- Site Number : 8400019, Birmingham
RECRUITING
Investigational Site Number : 2760002, Göttingen
RECRUITING
Investigational Site Number : 7240003, Valencia
RECRUITING
Investigational Site Number : 2760004, Tübingen
RECRUITING
Investigational Site Number : 2500001, Le Kremlin-Bicêtre
RECRUITING
Investigational Site Number : 1560013, Beijing
RECRUITING
Investigational Site Number : 1560005, Beijing
RECRUITING
Investigational Site Number : 1560001, Shanghai
RECRUITING
Investigational Site Number : 1560002, Fuzhou
RECRUITING
Investigational Site Number : 1560003, Wuhan
RECRUITING
Investigational Site Number : 1560011, Chengdu
RECRUITING
Investigational Site Number : 1520002, Santiago
RECRUITING
University of Kansas Medical Center (KUMC)- Site Number : 8400010, Westwood
RECRUITING
Investigational Site Number : 1240001, Gatineau
RECRUITING
Investigational Site Number : 1240002, Québec
RECRUITING
Investigational Site Number : 3800002, Roma
RECRUITING
Investigational Site Number : 5280001, Amsterdam
RECRUITING
Investigational Site Number : 6160001, Lublin
RECRUITING
Investigational Site Number : 4100003, Seoul
RECRUITING
Investigational Site Number : 7240002, Barcelona
RECRUITING
Investigational Site Number : 7240001, Barcelona
Lead Sponsor
Sanofi
INDUSTRY